Cancer Clinical Trial in Australia

ERX-315 Clinical Trial Now Open in Australia

A new investigational drug for patients with advanced cancer.

ERX-315 represents a new potential approach to fighting cancer. Unlike traditional treatments that affect both healthy and cancerous cells, this innovative new investigational drug is designed to specifically target cancer cells by blocking the proteins they need to survive. In laboratory studies, ERX-315 has shown ability to stop cancer growth and kill cancer cells.

What Makes ERX-315 Different?

This clinical trial is open to adults who:
• Are 18 years or older• Have been diagnosed with Advanced/metastatic solid tumor no longer responding to therapy • Have tried other treatments that are no longer controlling the cancer• Your study doctor will confirm full inclusion/exclusion criteria• Both men and women are welcome to participate.

Are You Eligible?

• You will gain access to a new treatment that is not available anywhere else. In fact, ERX-315 can only be given to patients in this clinical trial.• You may benefit from this new treatment• You will receive care from a specialized team of cancer doctors• You will be helping advance research that may benefit others in the future.

Why should I join a clinical trial?

A Phase 1 Trial of ERX-315 in Participants
with Advanced Solid Tumors

Where to enroll:
• The Kinghorn Cancer Center• Cancer Research SAContact: Kelly Mead.+61 (8) 8359 2565 / admin@crsa.au• MQ Health Medical Oncology and Clinical Trials at Macquarie University.Contact: Luke Wood.+61 (2) 9812 2956 / clinicaltrials@mq.edu.au• Icon Cancer Center Adelaide.Contact: Anna Mislang.+61 (8) 8474 0220 / admin.adelaide@icon.team

For full trial details, please visit ClinicalTrials.gov

Where can a patient enroll?

What to Expect

Comprehensive Support
• Screening to confirm eligibility
• Detailed explanation of everything before you decide
• Time to discuss with family and your regular doctor

Treatment Schedule
• Regular clinic visits for study-medicine administration
• Safety tests, imaging and other assessments per protocol
• Follow-up visits

You Have Control
• You can leave the study at any time, for any reason
• No pressure - the decision is entirely yours

Frequently Asked Questions

Q: Is ERX-315 approved?
A: No. ERX-315 is investigational.
Q: What types of cancer is ERX-315 being tested for?
A: It is intended for advanced metastatic solid tumors that have failed one or more therapies.
Q: Will I benefit from being in this study?
A: Participation may or may not benefit you. This Phase 1 study is not designed to determine benefit.
Q: Do I need to be in Australia to participate in the ERX-315 clinical trial?
A: Yes. The only sites currently recruiting are in Australia: The Kinghorn Cancer Center and MQ Health in Sydney and Cancer Research SA in Adelaide. You will need to go to one of these locations for treatment and tests.
Q: Is it safe?
A: Unknown. Safety and tolerability are being studied in Phase 1.
Q: What costs are covered?
A: The study covers the investigational medicine and study-specific procedures. Standard medical care may be billed per site policy. The study team can provide details.
Q: Can I leave the study?
A: Yes. You may withdraw at any time.

Ready to Learn More?

Your next step is simple:
• Talk to your oncologist - they can help determine if this trial suits your situation
• Ask questions - we encourage you to learn everything you want to know
• Take your time - there's no rush to decide
For complete eligibility details: visit ClinicalTrials.gov

If you are interested in joining this phase 1 trial of ERX-315 please review ClinicalTrials.gov then contact one of the currently enrolling clinical trial sites to discuss elegibility and scheduling.

Please reference “ERX-315 Phase 1 (NCT06533332)” in your inquiry.

Would you like to enroll? Do you have questions?

Where to find us